Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Clonal hematopoiesis and elevated ferritin are highly predictive of prolonged cytopenias in BCMA CAR T-treated patients; 9% developed secondary myeloid diseases, including high-grade MDS associated with expansion of TP53-mutated clones.”
Title: Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapy
Authors: Zachary M. Avigan, Jerrel Catlett, Saoirse Bodnar, Darren Pan, Adolfo Aleman, Tianxiang Sheng, Erin Moshier, Adriana C. Rossi, Shambavi Richard, Gurbakhash Kaur, Joshua Richter, Larysa J. Sanchez, Cesar Rodriguez, Hearn Jay. Cho, Shafinaz Hussein, Christian Salib, Lewis R. Silverman, Sundar Jagannath, Samir Parekh, Santiago Thibaud
You can read the Full Article on Clinical Cancer Research.
You can find more posts featuring Robert Orlowski on OncoDaily.
